ONCR-177, our lead candidate, is an intratumorally administered oncolytic Herpes Simplex Virus-1 (HSV-1) viral immunotherapy for the treatment of multiple solid tumor cancers. ONCR-177 fights tumors through multiple mechanisms, including inherent oncolytic activity, immune stimulation elicited by viral infection and the expression of five transgenes (IL-12, CCL4, FLT3LG, anti-PD-1 and anti-CTLA-4).
Learn more about our HSV-1 Platform
In preclinical studies, we have observed durable virus and immune system-driven anti-tumor activity in injected tumors as well as abscopal activity. We have also observed that ONCR-177 is well tolerated in a validated animal safety model of HSV-1 when administered intravenously.
Learn more about our preclinical findings
We are currently enrolling patients in a Phase 1, open-label, multi-center study of ONCR-177 alone and in combination with PD-1 blockade in adult subjects with advanced and/or refractory cutaneous, subcutaneous or metastatic nodal solid tumors (ClinicalTrials.gov Identifier: NCT04348916). The purpose of the study is to assess the safety and tolerability of ONCR-177 alone and in combination with PD-1 blockade and to determine the maximum tolerated dose and recommended Phase 2 dose, as well as to evaluate preliminary efficacy.
For more information, please visit: https://clinicaltrials.gov/ct2/show/NCT04348916